Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis
Abstract Background Passive immunization against RSV (Respiratory Syncytial Virus) is given in most western countries (including Israel) to infants of high risk groups such as premature babies, and infants with Congenital Heart Disease or Congenital Lung Disease. However, immunoprophylaxis costs are...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Livre |
| Publié: |
BMC,
2018-12-01T00:00:00Z.
|
| Sujets: | |
| Accès en ligne: | Connect to this object online. |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Cote: |
A1234.567 |
|---|---|
| Exemplaire 1 | Disponible |